Targeting Peripheral α5-GABAa Receptors for Chronic Pain: Translational Evidence & Clinical Proof of Concept
1:30 pm - Wednesday 27th January 2027
- Exploring the rationale for selectively modulating peripheral α5-GABAA receptors to alleviate neuropathic pain while minimizing central nervous system adverse effects
- Reviewing Phase 2 clinical results with SR750 in trigeminal neuralgia and implications for broader peripheral neuropathic pain populations
- Evaluating the potential of α5-GABAA receptor modulation as a differentiated non-opioid alternative to current standards of care such as gabapentinoids
- Expanding development across diabetic peripheral neuropathy, post-herpetic neuralgia and other chronic neuropathic pain indications